T. Rowe Price Investment Management
BIIB icon

T. Rowe Price Investment Management’s Biogen BIIB Stock Holding History

T. Rowe Price Investment Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$213M Sell
1,160,989
-9,918
-0.8% -$1.83M 0.15% 159
2025
Q4 		$206M Buy
1,170,907
+103,425
+10% +$16.9M 0.13% 167
2025
Q3 		$150M Sell
1,067,482
-326,994
-23% -$44.2M 0.09% 212
2025
Q2 		$175M Sell
1,394,476
-1,265,814
-48% -$158M 0.11% 195
2025
Q1 		$364M Sell
2,660,290
-439,496
-14% -$62.8M 0.24% 112
2024
Q4 		$474M Sell
3,099,786
-1,156,500
-27% -$195M 0.29% 99
2024
Q3 		$825M Sell
4,256,286
-1,422,573
-25% -$298M 0.5% 61
2024
Q2 		$1.32B Buy
5,678,859
+508,889
+10% +$111M 0.83% 28
2024
Q1 		$1.11B Sell
5,169,970
-187,356
-3% -$43.9M 0.68% 40
2023
Q4 		$1.39B Buy
5,357,326
+602,335
+13% +$148M 0.9% 23
2023
Q3 		$1.22B Buy
4,754,991
+1,355,921
+40% +$363M 0.86% 25
2023
Q2 		$968M Buy
+3,399,070
New +$1.01B 0.66% 36

Other funds holding BIIB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Investment Management's BIIB Position: Q1 2026 in Review

T. Rowe Price Investment Management reduced its Biogen (BIIB) stake by 0.85% in Q1 2026, selling an estimated $1.83M and leaving 1,160,989 shares worth $213M. The position accounts for 0.15% of the portfolio, ranked #159.

T. Rowe Price Investment Management first reported a position in BIIB in Q2 2023 and has held it in 12 quarters since. The position peaked at $1.39B in Q4 2023. 1,008 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • T. Rowe Price Investment Management held 1,160,989 shares of Biogen worth $213M as of Q1 2026.
  • T. Rowe Price Investment Management sold 9,918 Biogen shares in Q1 2026, an estimated $1.83M.
  • Biogen made up 0.15% of T. Rowe Price Investment Management's portfolio in Q1 2026, its #159 holding.
  • T. Rowe Price Investment Management first reported a position in Biogen in Q2 2023 and has held it in 12 quarters since.
  • T. Rowe Price Investment Management's Biogen position peaked at $1.39B in Q4 2023.
  • 1,008 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2026, filed 15 May 2026.